MindMed, a leader in psychedelic-inspired medicines, entered into a Sales Agreement on June 28, 2024, with Leerink Partners LLC to facilitate an at-the-market offering of its common shares. Under the agreement, MindMed may sell shares worth up to $150 million through Leerink Partners, acting as the sales agent. The company's common shares, traded on Nasdaq under the ticker symbol "MNMD," had a last reported sale price of $7.07 per share as of June 25, 2024.

The shares may be sold using any method classified as an "at the market offering" under the Securities Act of 1933. Leerink Partners is responsible for selling the shares on behalf of MindMed, with compensation set at up to 3.0% of the gross proceeds from each sale. As a sales agent, Leerink Partners will be considered an "underwriter" under the Securities Act, with their compensation deemed as underwriting commissions or discounts. MindMed has agreed to indemnify Leerink Partners against certain liabilities, including those under the Securities Act.

Hogan Lovells US LLP provided legal counsel for MindMed on U.S. matters, while Osler, Hoskin & Harcourt LLP advised on Canadian matters. Covington & Burling LLP served as legal counsel for Leerink Partners in connection with the offering. This offering presents a high degree of investment risk, as detailed in the accompanying prospectus and related documents.